489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.
July 2026 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may reduce depression risk in alopecia areata patients.
January 2024 in “Journal of Crohn's and colitis” This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.